CSIMarket
 
Orgenesis Inc   (ORGS)
Other Ticker:  
 
 
Price: $0.7892 $0.01 1.701%
Day's High: $0.8373 Week Perf: -3.94 %
Day's Low: $ 0.77 30 Day Perf: 131.44 %
Volume (M): 86 52 Wk High: $ 1.60
Volume (M$): $ 68 52 Wk Avg: $0.83
Open: $0.77 52 Wk Low: $0.25



 Market Capitalization (Millions $) 22
 Shares Outstanding (Millions) 28
 Employees 111
 Revenues (TTM) (Millions $) 36
 Net Income (TTM) (Millions $) 11
 Cash Flow (TTM) (Millions $) -1
 Capital Exp. (TTM) (Millions $) 10

Orgenesis Inc
Orgenesis Inc is a Delaware-based biotechnology company that specializes in the development of advanced cell therapy technologies and regenerative medicines. The company primarily focuses on developing and commercializing autologous cell therapies that can be used for treating a range of diseases, including diabetes, liver disease, and other chronic illnesses.

Orgenesis is headquartered in Germantown, Maryland, with offices and subsidiaries in Israel and Belgium. The company was founded by Dr. Dorit Arad and Dr. Sarah Ferber in 2008, and has since expanded its research and development capabilities to become a leading innovator in the field of cell therapy.

The company's core technology is the Orgenesis Diabetes Cell Therapy (ODCT) platform, which uses a patient's own liver cells to produce insulin in response to glucose levels. This novel approach to diabetes treatment has shown promising results in preclinical studies and clinical trials, offering a potential cure for millions of people living with the disease.

In addition to its work in diabetes, Orgenesis is also developing cell therapies for other chronic diseases and conditions, such as liver disease, pancreatitis, and other autoimmune disorders. The company is also collaborating with leading academic and research institutions, such as the University of California, San Francisco, to advance the field of cell therapy and regenerative medicine.

Orgenesis has a strong intellectual property portfolio, with multiple patents and patent applications for its cell therapy technologies. The company is also committed to responsible and sustainable business practices, with a focus on environmental stewardship, ethical standards, and social responsibility.

Overall, Orgenesis Inc is a leading biotechnology company that is at the forefront of developing innovative, patient-centric solutions for chronic diseases and conditions using advanced cell therapy technologies.


   Company Address: 20271 Goldenrod Lane Germantown 20876 MD
   Company Phone Number: 659-6404   Stock Exchange / Ticker: NASDAQ ORGS
   ORGS is expected to report next financial results on March 21, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Shares

Orgenesis Inc. Secures $2.3 Million Private Placement for Groundbreaking Cell and Gene Therapies

Published Mon, Mar 4 2024 1:30 PM UTC



Orgenesis Inc., a global leader in decentralized cell and gene therapies, recently announced an exciting development in the form of a definitive securities purchase agreement. In this agreement, accredited investors will purchase shares of the company's common stock, along with warrants to purchase additional shares, in a private placement. With expectations of app...

Financing Agreement

Orgenesis Consortium Secures 2.0M EUR Grant from Walloon Government to Revolutionize Decentralized ATMP Manufacturing with AI

Published Thu, Feb 29 2024 1:30 PM UTC

Orgenesis Consortium Awarded 2.0M EUR Grant from Walloon Government in Belgium for MAIDAM AI Project for Monitoring Decentralized ATMP Manufacturing
GERMANTOWN, Md., Feb. 29, 2024 - Orgenesis Inc. (Nasdaq:ORGS), the world-renowned global leader in decentralized cell and gene therapies (CGTs), proudly announces that its consortium has been honored with a significant 2.0 m...

Merger and Acquisition

Orgenesis Acquires Control of Octomera with the Goal of Progressing its Decentralized Immuno-Oncology Portfolio to Clinic

Published Wed, Jan 31 2024 2:15 PM UTC



In a strategic move aimed at solidifying its position in the rapidly expanding field of cell and gene therapies (CGTs), Orgenesis Inc. (Nasdaq: ORGS) has recently announced its definitive agreement to acquire a 25% stake in Octomera LLC. The Maryland-based global leader in decentralizing CGTs seeks to gain complete ownership of Octomera, its core cell processing se...

Orgenesis Inc

Orgenesis Inc Faces Steep Decline in Financial Performance, Revenue Drops by 3.138% in Q2 2023



In the April to June 30, 2023 timeframe, Orgenesis Inc, a major player in the pharmaceutical preparations sector, experienced a significant decline in several key financial metrics. With a drop in EPS, revenue, and net margin, the company faces an uphill battle in maintaining its profitability. Let's delve deeper into the financial results and examine them in context.
EPS and Revenue:
Orgenesis Inc's EPS dropped by a significant -31.82%, amounting to $0.15 per share compared to $0.22 in the corresponding period a year earlier. Moreover, the EPS decreased by -6.25% from $0.16 per share in the prior financial reporting period. These declining earnings indicate a struggle to generate profits and may raise concerns among investors.

Orgenesis Inc

Orgenesis Inc. Defies Global Economic Challenges with 6.6% Income Increase in Q1 2023, but Faces Urgency to Raise Performance Levels

19 as it isn't mentioned in the given article.
Orgenesis Inc, a company in the Major Pharmaceutical Preparations industry, recently announced its financial results for the first quarter of 2023. Despite the pandemic's impact on the global economy, Orgenesis achieved a 6.6% increase in income in the first quarter of 2023, reaching a cumulative value of $12 million. In addition, the company ended the first quarter with 111 employees, resulting in an income per employee growth on a trailing twelve-month basis to $112,009. However, this income per employee is still below the industry average, and the company must make adjustments to improve its performance.






 

Orgenesis Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com